MedPath

Clinical Study of Umbilical Cord Mesenchymal Stem Cells Combined With Collagen Scaffold in the Treatment of Thin Endometrium

Not Applicable
Completed
Conditions
Intrauterine Adhesion
Thin Endometrium
Interventions
Drug: umbilical cord mesenchymal stem cells combined with collagen scaffold
Registration Number
NCT03724617
Lead Sponsor
Sir Run Run Shaw Hospital
Brief Summary

This is a non-blind self-control trial. We mainly compare the changes of endometrial thickness,changes in menstrual flow, and improvement in pregnancy before and after stem cell treatment in patients with thin endometrium.

Detailed Description

According to the medical history and the results of the examination, the selected cases were screened and the informed consent was signed. After hysteroscopy, the collagen/umbilical cord mesenchymal stem cell was spread on a foley catheter, and placed in the uterine cavity, and 5 ml of saline was filled into the balloon. B-ultrasound confirmed that the stent was attached to the uterine wall. The balloon was removed in situ after 1 week. We mainly compare the endometrial thickness before and 6 months after surgery.

Recruitment & Eligibility

Status
COMPLETED
Sex
Female
Target Recruitment
18
Inclusion Criteria
  1. According to the GCP regulations, obtain the informed consent of the subject, volunteer for the test, and have signed the informed consent form.
  2. Women aged 20-40 years with fertility requirements
  3. Infertility patients who are treated in this hospital
  4. After more than 2 times of hysteroscopic adhesion separation surgery, the uterine cavity morphology has basically returned to normal. The patient has a normal menstrual cycle or an estrogenic dose of 6 mg per day, and the highest thickness of the endometrium is 5.5 mm in 6 cycles by ultrasound.
  5. or receive adjuvant reproductive treatment, the endometrial thickness is less than 5.5mm for unknown reasons, the treatment of estrogen, colony stimulating factor, aspirin, sildenafil and other drugs up to 8mg / day is invalid.
  6. HBVAg negative, HCV negative, HIV negative, syphilis negative
  7. Normal bone marrow morphology, normal blood routine
  8. Previously failed to receive relevant stem cell therapy
Read More
Exclusion Criteria
  1. Those who cannot accept the treatment observation process required by the test
  2. There are contraindications for hysteroscopic surgery;
  3. congenital uterine malformation; severe adenomyosis; uterine fibroids that may affect embryo implantation; the investigators judged that there are other uterine factors that are not suitable for embryo implantation
  4. Patients with chromosomal abnormalities
  5. contraindications to estrogen therapy; systemic diseases such as thrombosis, cardiopulmonary disease, hematopoietic diseases, malignant tumors, etc.
  6. Patients without fertility requirements
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
stem cell therapyumbilical cord mesenchymal stem cells combined with collagen scaffold-
Primary Outcome Measures
NameTimeMethod
the change of endometrial thicknessChange from Baseline endometrial thickness at 6 months

B-ultrasound measures and compares the endometrial thickness of the luteal phase before and after administration.

Secondary Outcome Measures
NameTimeMethod
pregnancy ratepregnancy rate at 1 year

pregnancy rate = (pregnancy / observations) × 100%

live birth ratelive birth rate at 1 year

live birth rate = (live births / observations) × 100%

abortion rateabortion rate at 1 year

abortion rate = (number of abortions / observations) × 100%

Trial Locations

Locations (1)

Sir Run Run Shaw hopital,School of medicine,Zhejiang University

🇨🇳

Hangzhou, China

© Copyright 2025. All Rights Reserved by MedPath